1. Home
  2. LPCN vs AKTX Comparison

LPCN vs AKTX Comparison

Compare LPCN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPCN
  • AKTX
  • Stock Information
  • Founded
  • LPCN N/A
  • AKTX N/A
  • Country
  • LPCN United States
  • AKTX United Kingdom
  • Employees
  • LPCN N/A
  • AKTX N/A
  • Industry
  • LPCN Biotechnology: Pharmaceutical Preparations
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPCN Health Care
  • AKTX Health Care
  • Exchange
  • LPCN Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • LPCN 36.8M
  • AKTX 37.4M
  • IPO Year
  • LPCN N/A
  • AKTX N/A
  • Fundamental
  • Price
  • LPCN $6.33
  • AKTX $3.88
  • Analyst Decision
  • LPCN Buy
  • AKTX
  • Analyst Count
  • LPCN 1
  • AKTX 0
  • Target Price
  • LPCN $33.00
  • AKTX N/A
  • AVG Volume (30 Days)
  • LPCN 43.3K
  • AKTX 25.0K
  • Earning Date
  • LPCN 08-08-2024
  • AKTX 05-16-2024
  • Dividend Yield
  • LPCN N/A
  • AKTX N/A
  • EPS Growth
  • LPCN N/A
  • AKTX N/A
  • EPS
  • LPCN N/A
  • AKTX N/A
  • Revenue
  • LPCN $4,711,366.00
  • AKTX N/A
  • Revenue This Year
  • LPCN N/A
  • AKTX N/A
  • Revenue Next Year
  • LPCN $81.58
  • AKTX N/A
  • P/E Ratio
  • LPCN N/A
  • AKTX N/A
  • Revenue Growth
  • LPCN 748.91
  • AKTX N/A
  • 52 Week Low
  • LPCN $2.31
  • AKTX $1.08
  • 52 Week High
  • LPCN $11.79
  • AKTX $5.50
  • Technical
  • Relative Strength Index (RSI)
  • LPCN 42.87
  • AKTX 64.21
  • Support Level
  • LPCN $7.50
  • AKTX $3.53
  • Resistance Level
  • LPCN $7.90
  • AKTX $3.91
  • Average True Range (ATR)
  • LPCN 0.59
  • AKTX 0.31
  • MACD
  • LPCN -0.25
  • AKTX 0.02
  • Stochastic Oscillator
  • LPCN 32.66
  • AKTX 93.54

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Share on Social Networks: